You are about to leave the Clinical Value website now.


Hepatocellular carcinoma surveillance: current practice and future directions

Quick Summary

The global incidence and mortality rates of hepatocellular carcinoma (HCC) are alarmingly high. Timely detection of HCC through surveillance is crucial for individuals with cirrhosis or other high-risk conditions to improve their overall survival. Although biannual ultrasonography with or without alpha-fetoprotein is currently the standard method for HCC surveillance, it has limited sensitivity in early-stage disease and may not be effective for some individuals.

This review article aims to comprehensively examine the current state of HCC surveillance, including the reasons and criteria for conducting HCC surveillance, conventional methods for HCC surveillance, and their advantages and disadvantages. Additionally, the review will discuss alternative surveillance methods such as cross-sectional imaging and emerging circulating biomarkers, as well as the issue of under-utilization of HCC surveillance and the potential harms associated with it.

You May Also Like

27 June 2024

Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand

Read More
13 May 2024

No woman left behind: Increasing access to testing for cervical cancer elimination

Read More
13 May 2024

Advancing women’s health: Project Teal drives cervical cancer screening in Hong Kong

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.